The exceptional genomic heterogeneity of TNBC, including its molecular subtypes, along with the lack of expression of hormone receptors and HER2, limits the possibilities of targeted therapy, as none of the hormonal therapy options or monoclonal antibodies used in other cancers show efficacy in this case [87]. The gene discussed is ERBB2; the disease is cancer.